05/16/2022 at 12:00 pm
Chronic hepatitis C virus (HCV) infection is associated with a 15- to 20-fold greater risk of hepatocellular carcinoma (HCC) compared to those without HCV. Individuals with HCV-related cirrhosis are at risk for HCC development, underscoring the importance of routine HCC surveillance in patients with HCV. Therefore, as a crucial component of HCV management, clinicians should integrate routine surveillance for HCC in patients with HCV, as recommended in current guidelines. Evidence shows that clinicians have misconceptions regarding appropriate tests to detect HCC and need to engage more in following HCC surveillance guidelines regarding screening intervals and imaging modality. To increase surveillance rates, it is crucial that all HCPs managing patients with HCV understand how to implement the most recent guidelines in practice.
This CMEO BriefCase will introduce a case involving the incorporation of routine surveillance for HCC in a patient with HCV. Join our faculty experts as they delve into the epidemiology and shared pathobiology of HCV and decompensated cirrhosis, identify compensated versus decompensated cirrhosis, and discuss surveillance strategies for HCC.
At the end of this CME/CE activity, participants should be able to integrate routine surveillance for HCC into clinical follow-up for patients with HCV.
Supported by an educational grant from Gilead Sciences, Inc.
U.S. and international physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in primary care
it is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Reau reports the following financial relationships: Consultant: AbbVie Inc.; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; and Merck & Co., Inc. Grants/Research Support: GENFIT; Intercept Pharmaceuticals, Inc.; and Shire
Dr. Kwo reports the following financial relationships: Advisory Board: AbbVie Inc.; Aligos Therapeutics Inc.; Ambys Medicines; Antios Therapeutics, Inc.; CVS; Eisai Inc.; Enanta Pharmaceuticals, Inc.; Gilead Sciences, Inc.; HepQuant; Mallinckrodt Pharmaceuticals; and Surrozen. Consultant: Drug Farm; Durect Corporation; Generon; Inventiva; Mirum Pharmaceuticals; and Syneos Health. Grants: Altimmune; Arrowhead Pharmaceuticals, Inc.; Assembly Biosciences, Inc.; Bristol Myers Squibb; Eiger BioPharmaceuticals; Novo Nordisk; Target RWE Registries; and Ultragenyx Pharmaceutical. Stock (Directly Purchased): Durect Corporation
Dr. Lim (Reviewer/Advisor) reports the following financial relationships: Research Support: Allergan; Celgene Corporation; Eiger BioPharmaceuticals, Inc.; GENFIT; Gilead Sciences, Inc.; Pfizer Inc.; and Viking Therapeutics
Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)
Kellie Busby, PharmD (planning committee)
Janan Sarwar, PharmD (planning committee)
Susan Perry (planning committee)
Susan H. Yarbrough, CHCP (planning committee)
Sharon Tordoff (planning committee)
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).